Table 4.

Change from Baseline to Last Assessment in Vital Signs (Patients with Nonmissing Values)

Vital Sign	Placebo, n = 59	Solriamfetol
		75 mg, n = 59	150 mg, n = 59	300 mg, n = 59	All Doses, n = 177
Patients with clinical laboratory assessment data at week 12, na	50	48	49	43	140
Heart rate, beats/min	0.5 ± 6.7	0.6 ± 6.6	2.5 ± 4.7	4.3 ± 7.6	2.4 ± 6.5
Blood pressure, mmHg
Systolic	0.6 ± 8.1	0.3 ± 6.8	1.2 ± 7.4	2.0 ± 7.4	1.2 ± 7.2
Diastolic	−0.6 ± 5.2	1.0 ± 4.4	1.4 ± 4.9	2.1 ± 5.0	1.5 ± 4.8
Ambulatory blood pressure monitoring in safety population at week 8, nb	50	46	46	41	133
Heart rate, beats/min	−0.6 ± 7.0	1.0 ± 8.0	0.7 ± 7.1	5.3 ± 7.6	2.2 ± 7.8
Blood pressure, mmHg
Systolic	−0.3 ± 9.3	1.8 ± 6.5	−0.5 ± 5.5	2.4 ± 6.0	1.2 ± 6.1
Diastolic	−0.1 ± 7.2	1.4 ± 5.1	0.4 ± 4.5	3.0 ± 5.0	1.6 ± 4.9

Values are mean ± standard deviation.

^aVital signs averaged across predose to 9 hours postdose.

^bVital signs matched by time point at baseline and week 8.